Zomedica Pharmaceuticals Corp. (ZOM) is a publicly traded company in the Unknown sector. Across all available filings, 15 corporate insiders have executed 87 transactions totaling $6.2M, demonstrating a bearish sentiment with -$5.0M in net insider flow. The most recent transaction on Sep 5, 2024 involved a purchase of 100,000 shares valued at $13.0K.
No significant insider buying has been recorded for ZOM in the recent period.
No significant insider selling has been recorded for ZOM in the recent period.
Based on recent SEC filings, insider sentiment for ZOM is bearish with an Insider Alignment Score of 10/100 and a net flow of -$5.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Zomedica Pharmaceuticals Corp. (ZOM) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 15 insiders are actively trading ZOM stock, having executed 87 transactions in the past 90 days. The most active insider is Robert Cohen (Executive), who has made 5 transactions totaling $3.8M.
Get notified when executives and directors at ZOM file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 5, 2024 | C. Heaton Larry II | Executive | Purchase | 100,000 | $0.13 | $13.0K | 10b5-1 |
| Aug 28, 2024 | D. Powers Johnny | Executive | Purchase | 100,000 | $0.13 | $13.0K | |
| Aug 20, 2024 | K. Blair Anthony | Executive | Purchase | 100,000 | $0.14 | $14.0K | |
| Jun 12, 2024 | Kevin Klass Russell | Executive | Purchase | 299,993 | $0.16 | $48.0K | |
| Jun 11, 2024 | Kevin Klass Russell | Executive | Purchase | 500,000 | $0.15 | $75.0K | |
| Jun 10, 2024 | Donato Peter | Executive | Purchase | 25,000 | $0.15 | $3.8K | |
| Jun 10, 2024 | Kevin Klass Russell | Executive | Purchase | 200,007 | $0.15 | $30.0K | |
| May 17, 2024 | D. Powers Johnny | Executive | Purchase | 50,000 | $0.17 | $8.5K | |
| May 17, 2024 | D. Powers Johnny | Executive | Purchase | 50,000 | $0.18 | $9.0K | |
| May 16, 2024 | D. Powers Johnny | Executive | Purchase | 25,000 | $0.18 | $4.5K | |
| May 14, 2024 | D. Powers Johnny | Executive | Purchase | 30,594 | $0.14 | $4.3K | |
| May 14, 2024 | D. Powers Johnny | Executive | Purchase | 19,406 | $0.14 | $2.7K | |
| May 13, 2024 | C. Heaton Larry II | Executive | Purchase | 100,000 | $0.14 | $14.0K | |
| May 13, 2024 | K. Blair Anthony | Executive | Purchase | 150,000 | $0.14 | $21.0K | |
| May 13, 2024 | D. Powers Johnny | Executive | Purchase | 100,000 | $0.14 | $14.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 29 | $5.6M | 49.7% |
Exercise(M) | 33 | $4.9M | 43.9% |
Purchase(P) | 24 | $618.7K | 5.5% |
Exercise (Options)(X) | 1 | $100.0K | 0.9% |
Insider selling pressure at Zomedica Pharmaceuticals Corp. has increased, with 15 insiders executing 87 transactions across all time. Total sales of $5.6M significantly outpace purchases of $618.7K, resulting in a net outflow of $5.0M. This selling activity appears largely discretionary, which may warrant closer attention from investors.